WINOBOLIC - Stanozolol 50mg

Category:- Hormones | Type:- Injection

Each ml contains: Stanozolol USP 50 mg

Read this entire leaflet carefully before you use this medicine

Indications and usage:
Hereditary angioedema: Winobolic is indicated prophylactically to decrease the frequency and severity of attacks of angioedema.

Contraindication: The use of Winobolic is contraindicated in the following:
1. Carcinoma of the prostate of breast in male patients.
2. Carcinoma of the breast in some females
3. Nephrosis or the nephritic phase of nephritis.
4 Hypercalcemia.
5. Winobolic can cause fatal harm when administered to a pregnant women If this drug is used during pregnancy or if the patient becomes pregnant while talking this drug, the patient should be apprised of the potential hazard to the foetus.

Drug interactions:
Anabolic steroids may increase sensitivity to anticoagulants: therefore, dosage of an anticoagulant may have to be decreased in order to maintain the prothrombin time at the desired therapeutic level.

Over dosage:
There have been no reports of acute over dosage with the androgens.

Precautions:
General: women should be observed for signs of virilisation (deepening of the voice, hirsutism, acne, and clitoromegaly). To prevent irreversible change, drug therapy must be discontinued, or the dosage significantly reduced. Such virilisation is usual following androgenic anabolic steroid use at high dosages. some virilising changes in women are irreversible even after prompt discontinuance of therapy and are not prevented by concorntant use of estrogens. Menstrual irregularities may also occur. The insulin or
oral hypoglycemic dosage may need adjustment in diabetic patients who receive anabolic steroids.

Information for the Patient: The physician should instruct patients to report any of the following side effects of androgens.

Adult or Adolescent Males: Too frequent or persistent erections of the penis, appearance of aggravation of acne.

Women: Hoarseness, acne changes in menstrual periods, or more hair on the face.

All Patients: Any nausea, vomiting, changes in skin colour, or ankle swelling.

Laboratory Test: Women with disseminated breast carcinoma should have frequent determination of urine and serum, calcium levels. Because of the hepatotxicity associated with the use of 17-alpha-alkylated androgens, liver function tests should be obtained periodically. Periodic (every 6 months) x-ray examinations of bone age should be made during treatment of prepubertal patients to determine the rate of bone maturation and the effects of androgenric anabolic steroid, therapy on the epiphyseal
centres. In common with other anabolic steroid, Winobolic has been reported to lower the level of high-density lipoproteins and raise the level of low-density lipoproteins. These changes usually revert to normal on discontinuation of treatment. Increased low-density lipoproteins and decreased high-density lipoproteins and considered cardiovascular risk factors. Drug/Laboratory. Therapy with androgenic anabolic steroids may decrease levels of thyroxin binding globulin resulting in decreased totel T4 serum levels and increase resin uptake of T3 and T4, free thyroid hormone levels remain unchanged. Anabolic steroids may cause an increase in prothrombin time. Pregnancy Category X.

Nursing Mothers: Winobolic is not known whether anabolic steroids are excreted in human milk. Paediatric use. Anabolic agents may accelerate epiphyseal maturation more rapidly than linear growth in children, and the effect may continue for 6 months after the drug has been stopped. Therefore, therapy should be monitored by x-ray studied at 6 month intervals in order to avoid the risk of compromising the adult height. The safety and efficacy of Winobolic in children with hereditary angioedema have not been established.

Genitourinary System:
In men : Prepubertal: Phallic enlargement and increased frequency of erections. Postpubertal: Inhibition of testicular function, testicular atrophy and oligospermia, impotence, chronic priapism, epididymitid and bladder irritability.

In women: Clitoral enlargement. Menstrual irregularties.

In both sexes: increased or decreased libido.
CNS: habituation, excitation, insomnia, depression.

Hematologic: Bleeding in patients on concomitant anticoagulant therapy.
Hair: Hirsutism and male pattern baldness in women.

Skin: Acne.

Skeletal: Premature closure of epiphyses in children use.

Electrolytes: Edema, retention of serum electrolytes.

Metabolic/Endocrine: Decreased glucose tolerance increased serum levels of low-density lipoproteins and decreased levels of high-density lipoproteins increased creatine and creatinine excretion levels of creatinine phosphokinase. Some virilising changes in women are irreversible even after prompt discontinuance of therapy and are not prevented by concomitant use of estrogens.

Dosage and administration:
Hereditary Angloedems: The dosage requirements for continuous treatment of hereditary angioedema with Winobolic should be individualized on the basis of the clinical response of the patient.

How Supplied:
Winobolic is supplied in 10 x 1ml ampoule. Ampoules should be stored at controlled room temperatures below 30°C and protected from light. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Warming and shaking the ampoule should redissolve any crystals that may have formed during storage at temperatures lower than recommended. If it has expired or is damaged, return it to your pharmacist
for disposal.

Abuse in Sports:
Abuse of this product in sports is highly discouraged. Cooper Pharma does not take any responsibility for use of this product for any other purpose. This product should be used under proper medical supervision.

Keep out of the reach and sight of children.

Manufactured by :
COOPER PHARMA LIMITED